38.71
2.01 (5.48%)
| Penutupan Terdahulu | 36.70 |
| Buka | 36.50 |
| Jumlah Dagangan | 360,395 |
| Purata Dagangan (3B) | 1,188,220 |
| Modal Pasaran | 2,778,716,160 |
| Harga / Buku (P/B) | 4.17 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Aug 2026 |
| EPS Cair (TTM) | -3.00 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 10.18% |
| Nisbah Semasa (MRQ) | 27.68 |
| Aliran Tunai Operasi (OCF TTM) | -155.26 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -97.14 M |
| Pulangan Atas Aset (ROA TTM) | -23.46% |
| Pulangan Atas Ekuiti (ROE TTM) | -39.49% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Vera Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.0 |
| Purata | 1.25 |
|
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 3.97% |
| % Dimiliki oleh Institusi | 112.39% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 110.00 (HC Wainwright & Co., 184.16%) | Beli |
| Median | 99.00 (155.75%) | |
| Rendah | 88.00 (Wolfe Research, 127.33%) | Beli |
| Purata | 99.00 (155.75%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 41.23 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wolfe Research | 11 Mar 2026 | 88.00 (127.33%) | Beli | 42.04 |
| HC Wainwright & Co. | 02 Mar 2026 | 110.00 (184.16%) | Beli | 40.42 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |